Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NCT02420717
Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia
- NCT02420717 ↗
- Terminated
- M.D. Anderson Cancer Center
- Focused
We haven't built an HCP commentary report on NCT02420717 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT02420717 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase I-II Study of the Combination of Ruxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL)
- Phase
- Phase 2
- Status
- Terminated
- Conditions
- Recurrent B Acute Lymphoblastic Leukemia; Recurrent Ph-Like Acute Lymphoblastic Leukemia; Refractory B Acute Lymphoblastic Leukemia; Refractory Ph-Like Acute Lymphoblastic Leukemia
- Interventions
- Cyclophosphamide; Cytarabine; Dasatinib; Dexamethasone; Doxorubicin; Laboratory Biomarker Analysis; Leucovorin; Mercaptopurine; Methotrexate; Prednisone; Rituximab; Ruxolitinib Phosphate; Vincristine
- Arms
- Cohort A (ruxolitinib phosphate) · Experimental
- Cohort B (dasatinib) · Experimental
- Phase 1 · Experimental
- Enrollment
- 11
- Primary outcomes
- Maximal Tolerated Dose (MTD) of Ruxolitinib in Combination With Chemotherapy Defined as the Highest Dose Level at Which no More Than 1 Out of 6 Patients Experience a Dose Limiting Toxicity (Phase I)
- Participants With Complete Response (Complete Response [CR]/CR With Incomplete Marrow Recovery [CRi]) (Phase II)
- Sponsor
- M.D. Anderson Cancer Center with National Cancer Institute (NCI)
- Start
- Jul 15, 2015
- Primary completion
- Jan 20, 2021
- Results posted
- Yes
- Registry record
- NCT02420717 · updated Jun 8, 2025